GENIXCURE develops novel AAV vectors with its own AI system called InsightMiner™
and
it also develops wholly owned therapeutic programs against ALS, FTD, AD and Lafora disease.
CARE™(Cell-specific AAV Research Engine), AI-powered by InsightMiner™
Enhanced in-silico rAAV vectors featuring On- & De-targeting efficiency
Also featuring BBB penetration, immune evasion, and manufacturability of rAAVs
XOB031; an AAV9-based novel CNS vector
Developing programs based on its own rAAV vectors from CARE™
CNS-centric programs; ALS, FTD, AD, and Lafora disease
Partnering with pharmaceuticals to swiftly expand programs leveraged by CARE™
Dedicated team to gene therapy and neuroscience
Customized design & production of both plasmids and AAVs
Analysis & Quality Assurance services available
For more gene therapies helping patients suffering from intractable diseases
For beautiful youth and healthy aging